Granahan Investment Management LLC Has $4.99 Million Holdings in Immunome, Inc. $IMNM

Granahan Investment Management LLC lifted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 8.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 426,219 shares of the company’s stock after purchasing an additional 33,468 shares during the quarter. Granahan Investment Management LLC owned 0.46% of Immunome worth $4,991,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Schonfeld Strategic Advisors LLC bought a new stake in shares of Immunome in the third quarter valued at approximately $856,000. Creative Planning increased its stake in Immunome by 4.0% during the 3rd quarter. Creative Planning now owns 18,664 shares of the company’s stock worth $219,000 after acquiring an additional 710 shares during the period. Raymond James Financial Inc. increased its stake in Immunome by 168.2% during the 3rd quarter. Raymond James Financial Inc. now owns 10,300 shares of the company’s stock worth $121,000 after acquiring an additional 6,459 shares during the period. California State Teachers Retirement System raised its holdings in Immunome by 72.2% in the 3rd quarter. California State Teachers Retirement System now owns 65,845 shares of the company’s stock valued at $771,000 after acquiring an additional 27,605 shares in the last quarter. Finally, Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in Immunome in the 3rd quarter valued at $5,884,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Immunome

In related news, Director Isaac Barchas sold 383,200 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the sale, the director owned 2,031,181 shares in the company, valued at $44,157,874.94. The trade was a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Clay B. Siegall bought 4,729 shares of the stock in a transaction on Tuesday, December 30th. The stock was purchased at an average cost of $21.15 per share, with a total value of $100,018.35. Following the acquisition, the chief executive officer owned 665,254 shares in the company, valued at approximately $14,070,122.10. This represents a 0.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 69,518 shares of company stock valued at $1,475,508 in the last 90 days. 7.69% of the stock is owned by corporate insiders.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $20.36 on Monday. Immunome, Inc. has a one year low of $5.15 and a one year high of $27.65. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -8.41 and a beta of 2.12. The firm has a 50 day simple moving average of $22.73 and a 200 day simple moving average of $18.18.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative return on equity of 57.61% and a negative net margin of 1,687.08%. As a group, analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. HC Wainwright started coverage on Immunome in a report on Thursday, February 12th. They set a “buy” rating and a $40.00 target price on the stock. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Truist Financial started coverage on shares of Immunome in a research report on Monday, December 1st. They set a “buy” rating and a $36.00 price objective for the company. Stephens reduced their price objective on shares of Immunome from $33.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Finally, Evercore raised their target price on shares of Immunome from $18.00 to $40.00 and gave the company an “outperform” rating in a report on Tuesday, December 16th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immunome has a consensus rating of “Moderate Buy” and a consensus price target of $33.45.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.